| Epidemiologic and survival trends in amyloidosis, 1987–2019 S Ravichandran, HJ Lachmann, AD Wechalekar New England Journal of Medicine 382 (16), 1567-1568, 2020 | 111 | 2020 |
| Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis G Palladini, B Paiva, A Wechalekar, M Massa, P Milani, M Lasa, ... Blood cancer journal 11 (2), 34, 2021 | 58 | 2021 |
| Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis OC Cohen, A Ismael, B Pawarova, R Manwani, S Ravichandran, S Law, ... European heart journal 43 (4), 333-341, 2022 | 57 | 2022 |
| Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment A Martinez-Naharro, R Patel, T Kotecha, N Karia, A Ioannou, A Petrie, ... European heart journal 43 (45), 4722-4735, 2022 | 53 | 2022 |
| Characteristics and natural history of early-stage cardiac transthyretin amyloidosis S Law, M Bezard, A Petrie, L Chacko, OC Cohen, S Ravichandran, ... European heart journal 43 (27), 2622-2632, 2022 | 38 | 2022 |
| Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis MU Rauf, PN Hawkins, F Cappelli, F Perfetto, M Zampieri, A Argiro, ... European Heart Journal 44 (24), 2187-2198, 2023 | 31 | 2023 |
| Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage S Law, A Petrie, L Chacko, OC Cohen, S Ravichandran, JA Gilbertson, ... ESC Heart Failure 7 (6), 3942-3949, 2020 | 28 | 2020 |
| The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018 G Palladini, S Schönland, G Merlini, P Milani, A Jaccard, F Bridoux, ... Blood cancer journal 13 (1), 19, 2023 | 21 | 2023 |
| Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib S Ravichandran, OC Cohen, S Law, D Foard, M Fontana, ... Blood cancer journal 11 (6), 118, 2021 | 18 | 2021 |
| Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis OC Cohen, MH Brodermann, IJ Blakeney, S Mahmood, ... Amyloid 27 (3), 200-205, 2020 | 17 | 2020 |
| Commercial immunoglobulin products contain neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 spike protein V Upasani, K Townsend, MY Wu, EJ Carr, A Hobbs, G Dowgier, M Ragno, ... Clinical Infectious Diseases 77 (7), 950-960, 2023 | 15 | 2023 |
| Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy S Law, A Petrie, L Chacko, OC Cohen, S Ravichandran, JA Gilbertson, ... Heart 108 (6), 474-478, 2022 | 11 | 2022 |
| Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis OC Cohen, A Sathyanath, A Petrie, S Ravichandran, S Law, R Manwani, ... Heart 108 (20), 1616-1622, 2022 | 9 | 2022 |
| The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis OC Cohen, S Law, HJ Lachmann, F Sharpley, S Ravichandran, ... Blood Cancer Journal 10 (5), 60, 2020 | 9 | 2020 |
| Cardiac transplantation in transthyretin amyloid cardiomyopathy: outcomes from three decades of tertiary center experience Y Razvi, A Porcari, C Di Nora, RK Patel, A Ioannou, MU Rauf, A Masi, ... Frontiers in Cardiovascular Medicine 9, 1075806, 2023 | 8 | 2023 |
| Systemic light chain amyloidosis across Europe: key outcomes from a retrospective study of 4500 patients G Palladini, S Schönland, G Merlini, P Milani, A Jaccard, F Bridoux, ... Blood 138, 153, 2021 | 8 | 2021 |
| The experience of hereditary apolipoprotein AI amyloidosis at the UK National Amyloidosis Centre OC Cohen, IJ Blakeney, S Law, S Ravichandran, J Gilbertson, ... Amyloid 29 (4), 237-244, 2022 | 7 | 2022 |
| Long-term outcomes in light chain deposition disease-analysis of a UK cohort S Ravichandran, S Law, S Mahmood, B Wisniowski, D Foard, M Fontana, ... American Journal of Hematology 97 (12), E444-E446, 2022 | 7 | 2022 |
| NK/T cell lymphoma: a tertiary centre experience N Arora, A Mehta, S Ravichandran, I Arun, RB Achari, A Chakrapani, ... Indian Journal of Hematology and Blood Transfusion 33, 69-73, 2017 | 7 | 2017 |
| Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis S Ravichandran, S Law, S Mahmood, B Wisniowski, D Foard, M Fontana, ... Leukemia 36 (4), 1180-1184, 2022 | 6 | 2022 |
